← All trials
NCT04478305
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2021
- Primary completion
- Sep 30, 2021
- Completion date
- Sep 30, 2021
- First posted
- Jul 20, 2020
- Last posted
- Oct 22, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Western OntarioLead sponsor
- McMaster UniversityOverall official - principal investigator
- University of Western OntarioReponsible party - principal investigator
- PfizerCollaborator
- McMaster UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.